RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: The Company designs, develops, manufactures, and markets safety syringes (primarily the VanishPoint® syringe) and other safety medical products. Operations are based in Little Elm, Texas, with significant manufacturing capacity outsourced to Double Dove in China (approximately 74.5% of units in the first half of 2007). The Company faces market access challenges due to monopolistic practices by competitor Becton Dickinson (BD), though it maintains international contracts (e.g., PATH) and domestic sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline (QTD): Net sales decreased slightly to $5.27 million for the quarter compared to $5.30 million in the prior year quarter. However, "Total Sales" (including reimbursed discounts) dropped significantly from $7.44 million to $5.27 million because the litigation settlement discount reimbursement program ended on December 31, 2006.
• Revenue Growth (YTD): For the six months ended June 30, 2007, net sales increased 20.3% to $11.05 million compared to $9.18 million in the prior year period, driven by a 33.2% increase in international unit sales.
• Widening Losses: The net loss for the six months ended June 30, 2007, was $3.88 million, a significant increase from the $803,000 loss in the same period in 2006. This was driven by lower gross margins and a 22% increase in operating expenses.
• Operating Expenses: General and administrative expenses rose sharply due to increased legal fees. Sales and marketing expenses also increased year-to-date due to higher compensation and travel costs.
• Cash Flow: Net cash used by operating activities was $5.31 million for the six months ended June 30, 2007, compared to $612,000 used in the prior year. A significant portion ($1.7 million) was used to build inventory levels to insulate against supply disruptions.

Guidance, Outlook, and Risks

• Market Access: Management states that access to the hospital market remains difficult due to monopolistic practices by BD. The Company is pursuing strategies to gain better access through sales efforts and innovative technology.
• Litigation: The Company filed a new lawsuit against BD on June 15, 2007. It also maintains a lawsuit against Abbott Laboratories regarding marketing fees.
• International Expansion: The Company holds federal contracts to supply syringes to African countries (PATH). Royalties from a license agreement with BTMD (China) are not expected to begin until 2008 due to delays in government approvals.
• Liquidity: The Company holds approximately $41 million in cash. Management states it has sufficient reserves to fund operations but may implement cost-cutting measures (workforce reduction, salary reductions, royalty deferrals) if market access remains limited and cash from operations becomes insufficient.
• Preferred Stock Dividends: Significant dividends are in arrears on Series III, IV, and V Class B Convertible Preferred Stock, totaling over $11.8 million in cumulative arrearages as of June 30, 2007.

Investor Verification Checklist

• Reimbursement Revenue: Verify the cessation of "Reimbursed discounts" revenue, which contributed significantly to prior year totals but is now zero.
• Legal Exposure: Review the details of the new lawsuit filed against BD on June 15, 2007, and the ongoing litigation with Abbott Laboratories.
• Preferred Stock Arrears: Confirm the total amount of dividends in arrears on Class B Preferred Stock and the implications for common shareholder dividends.
• Inventory Build: Assess the rationale and risk associated with the $1.7 million cash outflow used to increase inventory levels.
• BTMD Royalties: Monitor the status of the BTMD license agreement in China, specifically the timeline for government approvals and the start of royalty payments (currently expected no earlier than 2008).